JP2022517399A - Cd38に特異的な二環式ペプチドリガンド - Google Patents

Cd38に特異的な二環式ペプチドリガンド Download PDF

Info

Publication number
JP2022517399A
JP2022517399A JP2021541187A JP2021541187A JP2022517399A JP 2022517399 A JP2022517399 A JP 2022517399A JP 2021541187 A JP2021541187 A JP 2021541187A JP 2021541187 A JP2021541187 A JP 2021541187A JP 2022517399 A JP2022517399 A JP 2022517399A
Authority
JP
Japan
Prior art keywords
seq
referred
sar
peptide ligand
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021541187A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517399A5 (https=
JPWO2020148530A5 (https=
Inventor
バルダッサーレ レオナルド
ラニ ラシッド
パヴァン シルヴィア
ステイス キャサリン
トイフェル ダニエル
Original Assignee
バイスクルアールディー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイスクルアールディー・リミテッド filed Critical バイスクルアールディー・リミテッド
Publication of JP2022517399A publication Critical patent/JP2022517399A/ja
Publication of JP2022517399A5 publication Critical patent/JP2022517399A5/ja
Publication of JPWO2020148530A5 publication Critical patent/JPWO2020148530A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021541187A 2019-01-15 2020-01-15 Cd38に特異的な二環式ペプチドリガンド Pending JP2022517399A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1900530.5 2019-01-15
GBGB1900530.5A GB201900530D0 (en) 2019-01-15 2019-01-15 Bicyclic peptide ligands specific for CD38
PCT/GB2020/050074 WO2020148530A1 (en) 2019-01-15 2020-01-15 Bicyclic peptide ligands specific for cd38

Publications (3)

Publication Number Publication Date
JP2022517399A true JP2022517399A (ja) 2022-03-08
JP2022517399A5 JP2022517399A5 (https=) 2023-01-25
JPWO2020148530A5 JPWO2020148530A5 (https=) 2023-01-25

Family

ID=65528178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021541187A Pending JP2022517399A (ja) 2019-01-15 2020-01-15 Cd38に特異的な二環式ペプチドリガンド

Country Status (6)

Country Link
US (1) US20220133733A1 (https=)
EP (1) EP3911366A1 (https=)
JP (1) JP2022517399A (https=)
CN (1) CN113597317A (https=)
GB (1) GB201900530D0 (https=)
WO (1) WO2020148530A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6882978B2 (ja) 2014-10-29 2021-06-02 バイスクルアールディー・リミテッド Mt1−mmpに特異的な二環性ペプチドリガンド
JP7301757B2 (ja) 2017-06-26 2023-07-03 バイスクルアールディー・リミテッド 検出可能部分を持つ二環式ペプチドリガンドおよびその使用
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
US12551567B2 (en) 2018-12-21 2026-02-17 Bicyclerd Limited Bicyclic peptide ligands specific for PD-L1
JP2022514618A (ja) 2018-12-21 2022-02-14 バイスクルテクス・リミテッド Pd-l1に特異的な二環式ペプチドリガンド
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
IL300248A (en) 2020-08-03 2023-03-01 Bicycletx Ltd peptide-based linkers
GB202016331D0 (en) * 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
CN118388598A (zh) * 2024-04-22 2024-07-26 苏州大学附属第一医院 标记前体、探针及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514104A (ja) * 2002-12-12 2006-04-27 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル.ピー. グリコーゲンシンターゼキナーゼ−3阻害剤
JP2017519041A (ja) * 2014-05-21 2017-07-13 シクロポーターズ,インコーポレイテッド 細胞膜透過性ペプチド、並びにこの作製方法及び使用方法
US20180118786A1 (en) * 2015-04-28 2018-05-03 Ecole Polytechnique Federale De Lausanne (Epfl) NOVEL lNHIBITORS OF THE ENZYME ACTIVATED FACTOR XII (FXIIA)
WO2019002842A1 (en) * 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
DK2511297T3 (en) 2004-02-06 2015-06-15 Morphosys Ag Human anti-CD38 antibodies and their applications
DK1844337T3 (da) 2005-01-24 2013-09-30 Pepscan Systems Bv Bindingsforbindelser, immunogene forbindelser og peptidmimetika
EP2567976B1 (en) * 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
AU2009211253B2 (en) 2008-02-05 2014-11-06 Bicyclerd Limited Methods and compositions
JP6882978B2 (ja) 2014-10-29 2021-06-02 バイスクルアールディー・リミテッド Mt1−mmpに特異的な二環性ペプチドリガンド
GB201810320D0 (en) * 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514104A (ja) * 2002-12-12 2006-04-27 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル.ピー. グリコーゲンシンターゼキナーゼ−3阻害剤
JP2017519041A (ja) * 2014-05-21 2017-07-13 シクロポーターズ,インコーポレイテッド 細胞膜透過性ペプチド、並びにこの作製方法及び使用方法
US20180118786A1 (en) * 2015-04-28 2018-05-03 Ecole Polytechnique Federale De Lausanne (Epfl) NOVEL lNHIBITORS OF THE ENZYME ACTIVATED FACTOR XII (FXIIA)
WO2019002842A1 (en) * 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIUHONG CHEN, ET AL.: "The Bicycle platform: an efficient technology to generate high affinity, high selectivity molecules", BICYCLE THERAPEUTICS PUBLICATIONS [ONLINE], JPN6023022584, 2017, ISSN: 0005360628 *

Also Published As

Publication number Publication date
EP3911366A1 (en) 2021-11-24
GB201900530D0 (en) 2019-03-06
US20220133733A1 (en) 2022-05-05
CN113597317A (zh) 2021-11-02
WO2020148530A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
JP2022517399A (ja) Cd38に特異的な二環式ペプチドリガンド
TWI862640B (zh) 異質雙環肽複合物
JP7503689B2 (ja) EphA2に特異的な二環ペプチドリガンド
JP2022517040A (ja) Cd38に特異的な二環式ペプチドリガンド
JP2022514687A (ja) Pd-l1に特異的な二環式ペプチドリガンド
JP2022514255A (ja) Psmaに特異的な二環式ペプチドリガンド
JP2022517442A (ja) Caixに特異的な二環式ペプチドリガンド
JP2024023291A (ja) 多量体二環式ペプチドリガンド
JP2022517698A (ja) インテグリンαvβ3に特異的な二環式ペプチドリガンド
JP2022514618A (ja) Pd-l1に特異的な二環式ペプチドリガンド
JP2022518695A (ja) Caixに特異的な二環式ペプチドリガンド
JP2022552839A (ja) 二環式ペプチドリガンド薬物コンジュゲート
JP2022518210A (ja) インテグリンαvβ3に特異的な二環式ペプチドリガンド
JP2022532134A (ja) Ox40に特異的な二環式ペプチドリガンド
JP2022513223A (ja) Mt1-mmpに特異的な二環式ペプチドリガンド
JP2022513806A (ja) Mt1-mmpに特異的な二環式ペプチドリガンド
JP2020529427A (ja) Cd137に対して特異的な二環式ペプチドリガンド
JP2022512478A (ja) Mt1-mmpに特異的な二環式ペプチドリガンド
JP2021528432A (ja) Cd38に結合するためのペプチドリガンド
JP2022515720A (ja) Il-17に特異的な二環式ペプチドリガンド
CN117203219A (zh) 特异性针对p-选择素的双环肽配体
JP2022515721A (ja) FAPαに特異的な二環式ペプチドリガンド
WO2022079445A1 (en) Bicyclic peptide ligand drug conjugates
CN118234517A (zh) 双环肽配体药物偶联物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240702